Integer Board Chair Steps Down, Spence to Take Over
Event summary
- Pamela G. Bailey, Integer’s independent Chair of the Board, will not stand for re-election at the 2026 Annual Meeting of Stockholders on May 20, 2026.
- Donald J. Spence, current director, will succeed Bailey as independent Chair of the Board.
- Spence has served on the Board since 2016 and previously held executive roles at Ebb Therapeutics, Lake Region Medical, and Philips Respironics.
- Integer is a leading global medical device contract development and manufacturing organization (CDMO).
The big picture
Integer's board leadership transition comes at a time when the medical device CDMO sector is facing intense competition and rapid technological changes. The shift from Pamela G. Bailey to Donald J. Spence signals a potential strategic realignment, with Spence's extensive experience in the industry likely to influence the company's future direction. The transition underscores the importance of governance in navigating market dynamics and delivering sustainable value to shareholders.
What we're watching
- Governance Dynamics
- How the transition in board leadership will impact Integer's strategic direction and long-term value creation.
- Execution Risk
- Whether Donald J. Spence can maintain the momentum and strategic success achieved under Pamela G. Bailey's leadership.
- Industry Trends
- The pace at which Integer can adapt to evolving market dynamics and competitive pressures in the medical device CDMO space.
Related topics